Ilustrato Pictures International Inc (ILUS): That has bee true for months, maybe year...

That has bee true for months, maybe years.

nsomniyak · 2024-10-02T17:15:43.7000000Z

That has bee true for months, maybe years. A long time.

Play Episode

6min

Proactive - Interviews for investors

Pantheon Resources provides update on MEGREZ-1 flow testing results

Pantheon Resources Chairman David Hobbs and CEO Max Easley joined Steve Darling from Proactive to share preliminary flow test results from the Megrez-1 well in Alaska. The well is part of a six-interval testing program, and the first interval tested, the Topset 1 (TS1) reservoir, was fracture stimulated across 290 feet between 7,165 and 7,453 feet measured depth (MD). The well produced sustained strong liquid rates for 12 days, exceeding 1,000 barrels per day by the end of the flow-back period. However, no appreciable hydrocarbons were recovered during this initial test. Despite this, Easley noted the data reveals the TS1 reservoir is oil bearing but likely located within a transition zone that contains limited to no mobile oil or gas. Importantly, the technical data gathered from this interval has boosted the company's confidence in the five remaining, shallower intervals still to be tested. These higher zones are believed to hold greater potential for mobile hydrocarbons and increased productivity. TS1 will now be abandoned, and preparations are underway to begin testing the Lower Prince Creek interval. High-pressure pumping equipment is currently being mobilized to the Megrez pad. While the initial result may seem underwhelming at first glance, Pantheon emphasized that it strengthens their geological model and supports the likelihood of commercial success in the intervals yet to be tested. #proactiveinvestors #pantheonresourcesplc #mining #lse #panr #pthrf #OilAndGas #MEGREZ1 #FlowTesting #EnergyExploration #Hydrocarbons #AlaskaOil #OilDrilling #ResourceDevelopment #OilfieldUpdate

Proactive - Interviews for investors

Scancell fast-tracks melanoma study with NHS

Scancell Holdings PLC CEO Phillip L’Huillier joined Proactive's Stephen Gunnion with details of the company’s partnership with the NHS Cancer Vaccine Launchpad to accelerate patient recruitment for its SCOPE study evaluating the iSCIB1+ DNA cancer vaccine. L’Huillier described the deal as “a very positive endorsement for Scancell and for the medicines that we are developing,” noting that the therapy is showing promise in delivering long-term immune control in advanced melanoma patients. The NHS collaboration enables hospitals to more quickly access and offer the iSCIB1+ therapy as part of the trial, making Scancell the first UK company to partner with the platform and the first to offer a DNA cancer vaccine through it. He explained that the vaccine is given alongside checkpoint inhibitors, currently standard care, to boost response rates and prolong efficacy, especially where standard therapy alone sees limited, short-lived results. L’Huillier confirmed multiple SCOPE study data readouts are expected in 2025, with a larger development phase targeted for 2026. The company is also progressing its Modi-1 peptide vaccine and aims to further develop its GlyMab antibody platform, including the SC134 programme for small cell lung cancer. L’Huillier said his CEO priorities include sticking to development timelines, building strategic partnerships, and preparing the organisation for future phases. For more exclusive biotech interviews, visit Proactive's YouTube channel. Don't forget to like the video, subscribe to the channel, and enable notifications for future updates. #Scancell #CancerVaccine #BiotechNews #iSCIB1 #MelanomaResearch #NHSPartnership #DNAImmunotherapy #Modi1 #ClinicalTrials #OncologyInnovation #InvestorUpdate #ProactiveInvestors

Proactive - Interviews for investors

Futura Medical CEO James Barder on Futura’s 2024 strong growth, maiden profit and 2025 plans

Futura Medical PLC CEO James Barder takes Proactive's Stephen Gunnion through the company’s 2024 financial performance, market expansion and product pipeline. Futura reported a strong year in 2024, with CEO Barder highlighting revenue of £14 million and a maiden profit of £1.3 million—or £3.3 million excluding non-cash items. Barder noted that Eroxon is now sold in over 15 countries and is expected to reach over 20 by the end of 2025. “2024 was a very good year for us,” he said. Barder emphasised the company’s commitment to supporting commercial partners and building momentum behind its flagship product, Eroxon. He explained that markets seeing the most success were those effectively targeting men under 60 with mild to moderate erectile dysfunction—Eroxon’s most responsive user group. The conversation also touched on upcoming products, including Eroxon Intense, a variant delivering a stronger sensory experience, and SD4000, a topical treatment for female sexual dysfunction. Barder noted that 87% of women in clinical trials for SD4000 wished to continue use post-study—an encouraging sign. Looking ahead, Barder said the company will continue expanding its presence, drive forward its pipeline, and focus on areas it can control, despite share price frustrations. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to our channel, and hit the bell icon for updates. #FuturaMedical #Eroxon #EroxonIntense #SD4000 #ErectileDysfunction #FemaleHealth #PharmaNews #OTCProducts #HealthcareInnovation #BiotechUpdate

Proactive - Interviews for investors

Reconnaissance Energy Africa provides drilling update on Prospect I in Namibia

Reconnaissance Energy Africa CEO Brian Reinsborough joined Steve Darling from Proactive to share a drilling update on Prospect I, located onshore Namibia within Petroleum Exploration Licence 073. Prospect I represents the company’s largest exploration target to date. It is estimated to hold approximately 365 million barrels of unrisked and 32 million barrels of risked prospective light to medium oil resources, or alternatively, 1.9 trillion cubic feet of unrisked and 140 billion cubic feet of risked prospective natural gas resources, based on a 100% working interest. Reinsborough reported that pre-construction activities are progressing on schedule and that pre-drill evaluations have been successfully completed. Drilling is planned to reach a target depth of 3,800 metres, with the flexibility to drill deeper depending on subsurface conditions—similar to the company’s approach with the Naingopo exploration well. The Otavi geological section is anticipated to range between 1,500 and 1,800 metres in thickness, depending on total drilling depth. Insights gained from the Naingopo well have significantly enhanced ReconAfrica’s understanding of the Damara Fold Belt, particularly regarding time-depth migration and structural interpretation of the Mulden and Otavi formations. This same reservoir zone at Naingopo exhibited more than 50 metres of reservoir-quality carbonates and oil shows, underscoring its potential. These developments mark an important step in advancing ReconAfrica’s exploration strategy in one of Africa’s most promising onshore hydrocarbon basins. #proactiveinvestors #reconnaissanceenergyafricaltd #tsxv #reco #otcqx #recaf #NamibiaOil #ProspectI #OilExploration #EnergyUpdate #OnshoreDrilling #OilAndGasNews #AfricanEnergy #OilDiscovery #EnergyInvesting

Followers	296
Posts	21468
Boards Moderated	18
Alias Born	07/25/2003

Volume:	23,431,548
Day Range:	0.0021 - 0.0029
Bid:	0.002
Ask:	0.0024
Last Trade Time:	3:59:36 PM EDT
Total Trades:	161

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

ILUS Detailed Quote

Recent ILUS News

More ILUS News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent ILUS News

Go Ad-Free